Stay updated with breaking news from Dose Selection. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
- Announced agreement to be acquired by GSK for US$14.75 per share of common stock in cash representing an approximate total equity value of US$2.0 billion and a premium of approximately 103%;... | May 12, 2023
EQS-News: Vivoryon Therapeutics N.V. / Key word(s): Conference Vivoryon Therapeutics N.V.: Vivoryon Therapeutics to Present a Clinical Update on its Novel Oral Small Molecule Varoglutamstat
DGAP-News: Vivoryon Therapeutics N.V. / Key word: Study results/Study Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Presents Key Phase 2b Data at AAIC 2022 Showing that... | July 31, 2022
Safety data from 181 patients show no on-target toxicity and no clinical signs of ARIATherapeutic dose of 600 mg varoglutamstat given twice daily selected by the Data Safety Monitoring Board is known to
DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Study results/StudyVivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Presents Key Phase 2b Data at AAIC 2022 Showing that Varoglutamstat is Well Tolerated at Doses with High Target Inhibition, Highlighting Unique O (news with additional features)31.07.2022 /...